Artiva (ARTV) CEO sells 25,500 shares at $6 via 10b5-1 plan

Artiva Biotherapeutics (ARTV) reported an insider transaction on Form 4.

Accepted by SEC EDGAR 10/17/2025 - 08:44 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Artiva Biotherapeutics (ARTV) reported an insider transaction on Form 4. The President & CEO and Director sold 25,500 shares of common stock at $6 on 10/17/2025. Following the sale, the reporting person beneficially owned 356,721 shares, held directly.

The filing notes the trade was made under a Rule 10b5-1 trading plan adopted on July 23, 2024.

Insider Trade Summary

Net Seller: 25,500 shares

Net Sell 1 txn

Insider Aslan Fred

Role President and CEO

Sold 25,500 shs ($153K)

Share of Position Sold 6.7%

Type	Security	Shares	Price	Value
Sale	Common Stock	25,500	$6.00	$153K

Holdings After Transaction: Common Stock — 356,721 shares (Direct)

Holdings Before and After: Common Stock, 382,221 to 356,721 shares (Direct)

Footnotes (1)

1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ARTV’s insider report on Form 4?

A sale of 25,500 shares of common stock at $6 on 10/17/2025.

Who is the reporting person in ARTV’s Form 4?

The company’s President & CEO and Director.

How many ARTV shares does the insider own after the transaction?

Beneficial ownership is 356,721 shares, held directly.

Was the ARTV trade under a Rule 10b5-1 plan?

Yes. It was executed pursuant to a Rule 10b5-1 plan adopted on July 23, 2024.

What was the transaction code on the Form 4?

Code S, indicating an open-market or private sale.

Did the Form 4 report any derivative securities for ARTV?

No derivative transactions were reported in the excerpt provided.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aslan Fred

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
10/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/17/2025		S(1)		25,500	D	$6	356,721	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on July 23, 2024.

	/s/ Neha Krishnamohan, Attorney-in-Fact	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.